{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060536","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.072600+00:00","generated_at":"2026-06-02T02:20:01.267144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M","bullets":["Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.","Net loss of $11.7M narrowed from $22.1M YoY; non-GAAP net loss from operations $4.5M vs $14.9M.","YUPELRI total net sales $55.2M (by Viatris), +18% YoY; hospital doses sold up 31%.","Cash balance $100M; R&D expenses $9.0M down from $14.6M; SG&A $16.7M down from $19.2M.","Ampreloxetine CYPRESS enrollment continues; open-label enrollment expected H2 2024; KOL event May 23."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060536","json":"https://secwatch.observer/filing/0001104659-24-060536.json","markdown":"https://secwatch.observer/filing/0001104659-24-060536.md","text":"https://secwatch.observer/filing/0001104659-24-060536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/0001104659-24-060536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/tm2414185d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:20:01.267144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f69585588960026ed2f1380899bfeae74a5c9086","claim":"Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.","evidence_excerpt":"Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/0001104659-24-060536-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"Total revenue for the first quarter of 2024 was $14.5 million"},{"label":"Net income","value":"Net loss was $11.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}